Microbot Medical Strengthens Global IP with Issued Patent in India Covering the Company's ViRob Technology Platform Hingham, MA

Medical Strengthens Global IP with Issued Patent in India Covering the Company's ViRob Technology Platform

MA - June 25, 2018 - Microbot Medical Inc. (Nasdaq CM: MBOT), a medical device company specializing in the design

and development of transformational micro-robotic medical technologies, today announced that Intellectual Property India has granted

patent No. 296369, covering the Company's ViRob technology platform.

issued patent, coupled with the recent notices of patent allowance in China and the EU, again shows our commitment to expand,

grow and protect our assets in the developed, as well as the developing markets," commented Harel Gadot, CEO, President

and Chairman. "Based on the recently completed pre-clinical studies, in which leading hydrocephalus experts evaluated

the safety and potential clinical benefits of our Self-Cleaning Shunt (SCS) product, I believe that our SCS product,

which leverages the ViRob technology, can become the standard of care globally. The constituencies that are recognizing

our innovation represent sizeable market opportunities for our planned products."

Microbot Medical, Inc.

which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes

in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot's

current technological platforms platforms, ViRobTM, TipCATTM and CardioSertTM, are comprised

of three highly advanced technologies, from which the Company is currently developing its first product candidate: the Self Cleaning

Shunt, or SCSTM, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and focusing on the

development of a Multi Generation Pipeline Portfolio (MGPP) utilizing all technologies. Further information about Microbot Medical

is available at http://www.microbotmedical.com.

ViRobTM technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the

body. Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels,

the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages

as well as the ability to remain within the human body for prolonged time. To learn more about ViRobTM please visit

http://www.microbotmedical.com/technology/virob/.

is a transformational self-propelled, flexible, and semi-disposable endoscope providing see & treat capabilities within

tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly

suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve

the adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCATTM,

visit http://www.microbotmedical.com/technology/tipcat/.

technology is a unique combination of a guidewire and microcatheter, technologies that are broadly used for endoluminal

surgery. The CardioSertTM technology features unique steering and stiffness control capabilities, and it was originally

developed to support interventional cardiologists in crossing the most complex lesions called chronic total occlusion (CTO) during

percutaneous coronary intervention (PCI) procedures and has the potential to be used in other spaces and applications, such as

peripheral intervention, neurosurgery and urology. CardioSertTM was part of a technological incubator supported by

the Israel Innovation Authorities (formerly known as the Office of the Chief Scientist, or OCS), and its device has successfully

completed pre-clinical testing.

pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential

opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,

goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical

fact (including, but not limited to statements that contain words such as "will," "believes," "plans,"

"anticipates," "expects" and "estimates") should also be considered to be forward-looking

statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development

and/or commercialization of potential products, the outcome of its studies to evaluate the SCS and other existing and future technologies,

uncertainty in the results of pre-clinical and clinical trials or regulatory approvals, need and ability to obtain future capital,

and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking

statements and as such should be evaluated together with the many uncertainties that affect the businesses of Microbot Medical

Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.'s filings with the Securities

and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking statements.